New Indian study: High reliability of FTRD® for gastroduodenal lesions

gastroduodenal FTRD® demonstrates again its reliability for the treatment of upper GI subepithelial lesions, especially for duodenal neuroendocrine tumors (NETs)

Key findings

• 93.9% technical success rate (123/131)
• 77.9% overall R0 resection rate (102/131)
• 87.2% R0 resection rate for duodenal NETs (75/86)
• Low recurrence rate (3.9%; 4/103) over median 17 months follow-up
• One severe adverse event (major bleeding requiring no surgery)

Study details

• Multicenter, retrospective study at 14 Indian centers (April 2021–August 2024)
• 131 patients with gastroduodenal subepithelial lesions (SELs)
• Aim: Evaluation of clinical outcomes of FTRD® for upper GI SELs
• Indications: Predominantly duodenal (79.1%) and gastric (20.9%) SELs, especially NETs
• Median size of SELs: 12 mm

Nabi Z, Patil G, Puri R, Kothari T, Sud S, Chavan R, Sundaram S, Sonthalia N, Narayana J, Samanta J, Dhar J, Rajput S, Singla V, George J, Dhawan P, Goud R, Inavolu P, Maydeo AP, Sud R, Goenka M, Darisetty S, Reddy DN. Outcomes of device assisted endoscopic full thickness resection in gastroduodenal submucosal lesions: A large, multicentre study (with videos). Digestive and Liver Disease. 2025. DOI:10.1016/j.dld.2025.09.014.